The objective of this literature review is to familiarize the reader with the clinical data on selective estrogen receptor modulators (SERMs) and antiestrogens currently in use in the US, excluding data on breast effects. Four compounds in the SERM and antiestrogen families are presently in clinical use in the US: clomiphene (CC), tamoxifen (TAM), toremifene (TOR), and raloxifene (RLX). The clinical databse on these compounds is among the largest available. Each compound demonstrates a specific profile for its target tissue effects, and this may differ between premenopausal and postmenopausal women. CC is the most widely used agent for ovulation induction. TAM is indicated in the management of breast cancer and for prevention in women at high risk. TAM may have additional effects on the cardiovascular and skeleal systems. TOR also is used for its effects on breast tissue and may have positive cardiovascular effects. RLX is approved in the management of osteoporosis with data supporting favorable effects on the cardiovascular system and breast tissue. TAM and TOR appear to have stimulatory effects on the uterus and endometrium, whereas RLX is neutral. Few adverse events have been attributed to these agents, with hot flashes being the most common one. There appears to be an increased risk of thromboembolic events with continuous use of TAM, TOR, and RLX. SERMs and antiestrogens continue to be studied extensively. Their evolving profiles support key roles for these agents in modern day medicine, particularly in the management of postmenopausal women's health.
11. Stewart PJ, Stern PH. Effects of the antiestrogens tamoxifen and clomiphene on bone resorption in vitro. Endocrinol1986;8:125-131.
12.
12. Beall PT, Misra LK, Young RL, Spjut HJ, Evans HJ, LeBlanc A. Clomiphene protects against osteoporosis in the mature ovariectomized rat. Calcif Tissue Int1984;36:123-125.
13.
13. Ruenitz PC, Shen Y, Li M, et al. Specific bone-protective effects of metabolites/derivatives of tamoxifen and clomiphene in ovariectomized rats. Bone1998;23:537-542.
14.
14. Young RL, Goldzieher JW, Elkind-Hirsch K, Hickox PG, Chakraborty PK. A short-term comparison of the effects of clomiphene citrate and conjugated equine estrogen in menopausal/castrate women. Int J Fertil1991;36:167-171.
15.
15. Jones GS, de Moraes-Ruehsen M. Induction of ovulation with human gonadotropins and with clomiphene. Fertil Steril1965;16;461-461.
16.
16. Asch RH, Greenblatt RB. Update on the safety and efficacy of clomiphene citrate as a therapeutic agent. J Reprod Med1976;17:175-175.
22. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med1998;339:1609-1618.
23.
23. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomized trials. Lancet1998;351:1451-1467.
24.
24. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst1998;90:1371-1388.
25.
25. Kanis JA, McCloskey EV, Powles T, et al. A high incidence of vertebral fracture in women with breast cancer. Br J Cancer1999;79:1179-1181.
26.
26. Baker VL. Selective estrogen receptor modulators. Infertil Reprod Med Clin North Am1999;10:287-307.
27.
27. Barakat RR. Tamoxifen and endometrial neoplasia. Clin Obstet Gynecol1996;39:629-640.
28.
28. Lahti E, Blanco G, Kauppila A, et al. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obster Gynecol1993;81:660-664.
29.
29. Tomas E,Kauppila A, Blanco G, Apaja-Sakkinen M, Laatikainen T. Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients. Gynecol Oncol1995;59:261-266.
30.
30. Hulka CA, Hall DA. Endometrial abnormalities associated with tamoxifen therapy for breast cancer: Sonographic and pathologic correlation. Am J Roentgenol1993;160:809-812.
31.
31. Uziely B,Lewin A, Brufman G, Dorembus D, Mor-Yosef S. The effect of tamoxifen on the endometrium. Breast Cancer Res Treat1993; 26:101-105.
32.
32. Schwartz LB, Snyder J, Horan C, et al. The use of transvaginal ultrasound and saline infusion sonohysterography for the evaluation of asymptomatic postmenopausal breat cancer patients on tamoxifen. Ultrasound Ob-Gyn1998;11:48-53.
33.
33. Timmerman D, Deprest J, Bourne T, et al. A randomized trial on the use of ultrasonography or office hysteroscopy for endometrial assessment in postmenopausal patients with breast cancer who were treated with tamoxifen. Am J Obstet Gynecol1998;179:62-70.
34.
34. Goldstein SR. Selective estrogen receptor modulators: A new category of therapeutic agents for extending the health of postmenopausal women. Am J Obstet Gynecol1998;179:1479-1484.
35.
35. Goldstein SR. Unusual ultrasonographic appearance of the uterus in patients receiving tamoxifen. Am J Obstet Gynecol1994;170:447-451.
36.
36. Achiron R, Lipitz S, Sivan E, et al. Sonohysterography for ultrasonographic evaluation of tamoxifen-associated cystic thickened endometrium. J Ultrasound Med1995;14:685-688.
37.
37. Tepper R, Beyth Y, Altaras MM, et al. Value of sonohysterography in asymptomatic postmenopausal tamoxifen-treated patients. Gynecol Oncol1997;64:386-391.
38.
38. McGonigle KF, Shaw SL, Vasilev SA, et al. Abnormalities detected on transvaginal ultrasonography in tamoxifen-treated postmenopausal breast cancer patients may represent endometrial cystic atrophy. Am J Obstet Gynecol1998;178:1145-1150.
39.
39. CoheN I, Tepper R, Beyth Y. Ultrasonographic evaluation of endometrial disease in postmenopausal patients with breast cancer and tamoxifen treatment. Am J Obstet Gynecol1999;180:252-252.
40.
40. Barakat RR. Tamoxifen and the endometrium. Cancer Treat Res1998;94:195-207.
41.
41. McGonigle KF, Lantry SA, Odom-Maryon TL, et al. Histopathologic effects of tamoxifen on the uterine epithelium of breast cancer patients: Analysis by menopausal status. Cancer Lett1996;101:59-66.
42.
42. Ismail SM. Pathology of endometrium treated with tamoxifen. J Clin Pathol1994;47:827-833.
43.
43. Kennedy MM, Baigrie CF, Manek S. Tamoxifen and the endometrium: Review of 102 cases and comparison with HRT-related and non-HRT-related endometrial pathology. Int J Gynecol Pathol1999;18:130-137.
44.
44. Berliere M, Galant C, Gillerot S, et al. Endometrial evaluation prior to tamoxifen: Preliminary results of a prospective study. Bull Cancer1998;85:721-724.
45.
45. Smith LL, White IN. Antiestrogen therapy: Uncertainties and risk assessment. Oncology1998;12(3 suppl 5):14-22.
46.
46. Fornander T, Rutqvist LE, Cedermark B, et al. Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers. Lancet1989;1:117-120.
47.
47. Fisher B, Costantino JP, Redmond CK, et al. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst1994;86:527-537.
48.
48. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet1998;3511451-67.
49.
49. Jennings TS, Creasman WT. Effects on the reproductive tract: clinical aspects. In: Lindsay R, Dempster DW, Jordan VC, eds. Estrogens and antiestrogens, 1st ed.Philadelphia: Lippincott-Raven, 1997:223-242.
50.
50. Turken S, Siris E, Seldin D, et al. Effects of tamoxifen on spinal bone density in women with breast cancer. J Natl Cancer Inst1989;81:1086-1088.
51.
51. Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med1992;326:852-856.
52.
52. Ward RL, Morgan G, DAlleY D, Kelly PJ. Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women. Bone Miner1993;22:87-94.
53.
53. Grey AB, Stapleton JP, Evans MC, et al. The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women. Am J Med1995;99:636-641.
54.
54. Resch A, Biber E, Seifert M, Resch H. Evidence that tamoxifen preserves bone density in late postmenopausal women with breast cancer. Acta Oncol1998;37:661-664.
55.
55. Powles TJ, Hickish T, Kanis JA, et al. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopuasal and postmenopausal women. J Clin Oncol1996;14:78-84.
56.
56. Guetta V, Lush RM, Figg WD, et al. Effects of the antiestrogen tamoxifen on low-density lipoprotein concentrations and oxidation in postmenopausal women. Am J Cardiol1995;76:1072-1073.
57.
57. Grey AB, Stapleton JP, Evans MC, Reid IR. The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women. J Clin Endocrinol Metab1995;80:3191-3195.
58.
58. Love RR, Wiebe DA, Feyzi JM, et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after five years of treatment. J Natl Cancer Inst1994;86:1534-1539.
59.
59. Cattaneo M, Baglietto L, Zighetti ML, et al. Tamoxifen reduces plasma homocysteine levels in healthy women. Br J Cancer1998;77:2264-2266.
60.
60. Anker G, Lonning PE, Ueland PM, et al. Plasma levels of the atherogenic amino acid homocysteine in post-menopausal women with breast cancer treated with tamoxifen. Int J Cancer1995;60:365-368.
61.
61. Ilanchezhian S, Thangaraju M, Sachdanandam P. Plasma lipids and lipoprotein alterations in tamoxifen-treated breast cancer women in relation to the menopausal status. Cancer Biochem Biophys1995;15:83-90.
62.
62. Penotti M, Sironi L, Miglierina L, et al. The effect of tamoxifen and transdermal 17 beta-eestradiol on cerebral arterial vessels: A randomized controlled study. Am J Obstet Gynecol1998;178:801-805.
63.
63. McDonald CC, Stewart HJ. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee. BMJ1991;303:435-437.
64.
64. Walsh BW, Kuller LH, Wild RA, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA1998;279:1445-1451.
65.
65. McDonald CC, Alexander FE, Whyte BW, et al. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. The Scottish Cancer Trials Breast Group. BMJ1995;311:977-980.
66.
66. Rutqvist LE, Mattsson A. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. J Natl Cancer Instit1993;85:1398-1406.
67.
67. Costantino JP, Kuller LH, Ives DG, et al. Coronary heart disease mortality and adjuvant tamoxifen therapy. J Natl Cancer Inst1997;89:776-782.
68.
68. Robinson E, Kimmick GG, Muss HB. Tamoxifen in postmenopausal women: A safety perpsective. Drugs Aging1996;8:329-337.
69.
69. La Vecchia C, Tavani A, Garattini S. Adverse effects of preventive therapy in humans. IARC Scientific Publications (Lyon)1996;139:135-142.
70.
70. Ah-Song R, Sasco AJ. Tamoxifen and ocular toxicity. Cancer Detect Prev1997;21:522-531.
71.
71. HulleY S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA1998;280:605-613.
72.
72. Rosouw JE. What we still need to learn about hormone replacement therapy. Infertil Reprod Med Clin North Am1999;10:189-209.
73.
73. Ragaz J, Coldman A. Survival impact of adjuvant tamoxifen on competing causes of mortality in breast cancer survivors, with analysis of mortality from contralateral breast cancer, cardiovascular events, endometrial cancer, and thromboembolic episodes. J Clin Oncol1998;16:2018-2024.
74.
74. Kallio S, Kangas L, Blanco G, et al. A new trihenylethylene compound, Fc-1157a. I. Hormonal effects. Cancer Chemother Pharmacol1986;17:103-108.
76. Holli K. Adjuvant trials of toremifene versus tamoxifen: the European experience. Oncology1998;123 Suppl 5:23-27.
77.
77. Buzdar AU, Hortobagyi GN. Tamoxifen and toremifene in breast cancer: Comparison of safety and efficacy. J Clin Oncol1998;16:348-353.
78.
78. Marttunen MB, Hietanen P, Tiitinen A, Ylikorkala O. Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients. J Clin Endocrinol Metab1998;83:1158-1162.
79.
79. Saarto T, Blomqvist C, Ehnholm C, et al. Antiatherogenic effects of adjuvant antiestrogens: A randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer. J Clin Oncol1996;14:429-433.
80.
80. Gylling H, Pyrhonen S, Mantyla E, et al. Tamoxifen and toremifene lower serum cholesterol by inhibition of delta 8-cholesterol conversion to lathosterol in women with breast cancer.J Clin Oncol1995;13:2900-2905.
81.
81. Maenpaa JU, Ala-Fossi SL. Toremifene in postmenopausal breast cancer: Efficacy, safety and cost. Drugs Aging1997;11:261-270.
82.
82. Gershanovich M, Hayes DF, Ellmen J, Vuorinen. High-dose toremifene versus tamoxifen in postmenopausal advanced breast cancer. Oncology1997;115 Suppl 4:29-36.
83.
83. Pyrhonen S, Valavaara R, Modig H, et al. Comparison of toremifene and tamoxife in post-menopausal patients with advanced breast cancer: A randdomized double-blind, the “nordic” phase III study. Br J Cancer1997;76:270-277.
84.
84. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trail. JAMA1999;281:2189-2197.
85.
85. Delmas PD, Bjarnas on NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentration, and uterine endomentrium in postmenopausal women. N Engl J Med1997;337:1641-1647.
86.
86. Lufkin EG, Whitaker MD, Nickelsen T, et al. Treatment of established postmenopausal osteoporosis with raloxifene: A randomized trial. J Bone Miner Res1998;13:1747-1754.
87.
87. Ensud K, Black D, Recker S, et al. The effect of two and three years of raloxifene on vertebral and non-verterbal fractures in postmenopausal women with osteoporosis. Bone1998;23:S174-S174.
88.
88. Etinger B, Black D, Cummings S, et al. Raloxifene reduces the risk of incident vertebral fractures: 24-month interim analyses. Osteoporosis Intl1998;9Suppl 3:11-11.
89.
89. Mijatovic V, Netelenbos C, van der Mooren MJ, et al. Randomized, double-blind, placebo-controlled study of the effects of raloxifene and conjugated equine estrogen on plasma homocysteine levels in healthy postmenopausal women. Fertil Steril1998;70:1085-1089.
90.
90. Paul S, Dean RA, Tracy RP, et al. Effects of raloxifene and hormone replacement therapy on homocysteine and c-reactive protein levels in postmenopausal women. Circulation1998;98:17 Suppl:P1-P7.
91.
91. Goldstein SR, Scheele WH, Rajagopalan SK, et al. A 12-month comparative study of raloxifene, estrogen and placebo on the postmenopausal endometrium. Obstet Gynecol2000;95:95-103.
92.
92. Scheele WH, Symanowski SM, Neale S, et al. A high dose of raloxifene HCl is not stimulatory in the uterus of healthy postmenopausal women. In: XV FIGO World Congress of Gynecology and Obstetrics Annual Meeting Program; 1997 Aug 3-8; Copenhagen. Vojens: P. J. Schmidt A/S. p 20-20 (Abstract FC702.5).
93.
93. Scheele WH, Symanowski SM, Neale S, et al. Raloxifene does not cause stimulatory effects on the uterus in healthy postmenopausal women. In: The Endocrine Socity 79th Annual Meeting Program; 1997 June 11-14; Minneapolis. Bethesda (MD): The Endocrine Society Press. p 498-498 (Abstract P3-246).
94.
94. Glant MD, Scheele WH, Shah AS, et al. Raloxifene HCl is not stimulatory in the endometrium as assessed by an estrogenicity scoring system. In: IV European Congress on Menopause Abstract Book; 1997 Oct 8-12;Paris (FR): Editions ESKA. p 68-68 (Abstract FC6-1).
95.
95. Boss SM, Huster WJ, Neild JA, et al. Effects of raloxifene hydrochloride on the endomentrium of postmenopausal women. Am J Obstet Gynecol. 1997;177:1458-1464.
96.
96. Davies GC, Huster WJ, Shen W, et al. Endometrial effects of raloxifene assessed by bleeding rates, ultrasonographya nd biopsy. Menopause1998;5(4):282-282 (Abstract P-84).
97.
97. Jolly EE, Scheele WH, Shah AS, et al. A high dose of raloxifene HCl is not stimulatory in the uterus of healthy postmenopausal women. In: IV European Congress on Menopause Abstract Book. 1997 Oct 8-12; Paris (FR): Editions ESKA. p 68-68 (Abstract FC5-8).
98.
98. Goldstein S, Srikanth R, Parsons A, et al. Effects of raloxifene on the endometrium in healthy postmenopausal women. Menopause1998;5(4):277-277 (Abstract P-71).
99.
99. Davies GC, Huster WJ, Lu Y, et al. Adverse events reported by postmenopausal women in controlled trials with raloxifene. Obstet Gynecol1999;93:558-565.
100.
100. Bjarnason NH, Ennis M, Cummings SR, Christiansen C for the MORE study group. Associations between bone status and age in osteoporotic, postmenopausal women from 30-80. Osteoporosis International1998;8(Suppl 3):p 60-60 (Abstract P172).
101.
101. Anderson PW, Cox DA. Clinical trial evidence that raloxifene favorably affects surrogate markers of cardiovascular risk in postmenopausal women. Cardiovasc Rev Rep1999;20:1-6.
103. McDonnell DP. Selective estrogen receptor modulators (SERMS): A first step in the development of a perfect hormone replacement therapy regimen. J Soc Gynecol Investig2000;7Suppl:S10-S15.
